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Edited by Veli-Pekka LehtoAbstract Prostaglandin F2a (PGF2a) induces cyclin D1 expres-
sion and DNA synthesis in Swiss 3T3 cells. In order to assess
which signaling mechanisms are implicated in these processes,
we have used both a pharmacological approach and interfering
mutants. We demonstrate that PGF2a induces extracellular-sig-
nal-regulated kinase (ERK1-2) and p38
MAPK activation, and inhi-
bition of any of these signaling pathways completely blocks
PGF2a-stimulated DNA synthesis. We also show that ERK1-2,
but not p38MAPK activation is required to induce cyclin D1
expression, strongly suggesting that the concerted action of cy-
clin D1 gene expression and other events are required to induce
complete phosphorylation of retinoblastoma protein and S-phase
entry in response to PGF2a.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Prostaglandin F2a; MAPK; ERK1-2; p38
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Cyclin D1; S-phase1. Introduction
Mammalian cells proliferation is a highly coordinated phe-
nomenon generally regulated by growth factors and extracellu-
lar matrix adhesion [1–4]. Most growth factors bind and
activate receptors of tyrosine kinase, triggering the activation
of speciﬁc signal transduction pathways. These mitogen-in-
duced signals concertedly modulate the initiation of DNA rep-
lication and cell division, and this occurs by triggering a
cascade of events that ultimately induce the expression of G1
cyclins, key molecules that regulate crucial cell cycle transitions
[5–7]. Several lines of evidence support the idea that cyclin Ds
exert the main control on the transition of G0 to S phase [6,8],
and that most growth factors control G1 phase progression by
triggering the expression of cyclin Ds [9,10].Abbreviations: PGF2a, Prostaglandin F2a; ERK, extracellular-signal-
regulated kinase; MAPK, mitogen activated protein kinase; pRb,
retinoblastoma protein; FBS, fetal bovine serum; LIF, leukaemia
inhibitory factor; Me2SO, dimethyl sulfoxide
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doi:10.1016/j.febslet.2006.03.075Prostaglandin F2a (PGF2a) stimulates DNA synthesis and
proliferation of cultured Swiss mouse 3T3 cells [11], and is
implicated in unrestricted multiplication of transformed cells
[12]. Our previous work reveals that several PGF2a-triggered
signaling events are required to induce cellular entry into
S-phase, including increases in diacylglycerol, inositol 1,4,5-
trisphosphate, intracellular Ca2+ ion mobilization, and protein
kinase C (PKC) activation [11,13]. We have also shown that
PGF2a induction of cyclin D1 expression plays a pivotal role
in the control of DNA replication and the PGF2a-triggered
cyclin D1 expression involves a PKC-independent event, since
PGF2a is able to increase cyclin D1 mRNA/protein levels in
PKC-depleted cells [14]. Such a PKC-independent process
may correspond to other early PGF2a-triggered events and
both PKC-dependent and independent signals appear to be
concertedly required for cells to initiate DNA synthesis. Fur-
thermore, PGF2a appears to induce DNA synthesis via the
combined actions of the induction of cyclin D1 gene expression
and other signaling pathway-triggered events [14]. Thus, a ba-
sic question regarding PGF2a signaling mechanisms is whether,
and how, each personalized PGF2a signal regulates cyclin D1
expression, and how such events and others can ultimately
control initiation of DNA synthesis.
Here we report that PGF2a causes extracellular-signal-regu-
lated kinase (ERK1-2) and p38
MAPK activation in Swiss 3T3
cells. Using a pharmacological approach as well as stable
transfected cells with a dominant negative mutant of p38MAPK
we determined that ERK1-2 and p38
MAPK activation are essen-
tial for PGF2a-stimulated cellular entry into S-phase. We also
show that ERK1-2 but not p38
MAPK activation, is an essential
event required to induce cyclin D1 expression, suggesting that
p38MAPK activation is involved in eliciting another process dif-
ferent from cyclin D1 gene expression required to induce DNA
synthesis in response to PGF2a.2. Materials and methods
2.1. Cell culture
Swiss mouse 3T3 cells [15] were grown in DMEM containing 10% (v/
v) fetal calf serum. Sub-conﬂuent cultures were grown in 100-mm
dishes at 37 C equilibrated with 10% (v/v) CO2.
2.2. Initiation of DNA synthesis assay
DNA synthesis analysis was performed as previously described [4].
Brieﬂy, 1.5 · 105 cells were seeded in 35 mmdishes and growth until con-
ﬂuent andquiescent (6–8 days).Then cellswere stimulatedby additionofation of European Biochemical Societies.
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cessed for autoradiography. The percentage of cells that initiated DNA
synthesis at a given time was determined as previously described [4,16].
2.3. Transfection
For stable transfections, 106 cells/ml were electroporated with
pcDNA3.1 vector encoding ﬂag-tagged wild type or dominant-nega-
tive-p38MAPK[17]. After selection with G418 (400 lg/ml) and limiting
dilution, multiple resistant clones were isolated and tested for p38MAPK
expression using anti-ﬂag antibody. Cloned cells expressing the trans-
gene were analyzed for cell proliferation and protein expression. The
p38MAPK constructs were a kind gift of Dr. JiaHuai Han, Scripps Re-
search Institute, La Jolla, CA.
2.4. SDS–PAGE and immunoblotting
Protein extracts were prepared as in Sauane et al. [14]. Fifty micro-
grams of protein were separated on SDS–polyacrylamide gels and blot-
ted onto nitrocellulose membranes. Thereafter, membranes were
blocked and incubated overnight in the primary antibody diluted in
5% (w/v) non-fat milk in TBS-T. The primary antibodies used were:
phospho-ERK1-2 (#sc-7383), ERK2 (#sc-154), p38
MAPK (#sc-535),
cdk4 (#sc-260), cyclin D1 (#sc-450) from Santa Cruz Biotechnology;
phospho-p38MAPK (#9211) from Cell Signaling; Retinoblastoma
(pRb) (#14001A) from Pharmingen; ﬂag (#F3165) from Sigma. Mem-
branes were washed with TBS-T and incubated with peroxidase-conju-
gated secondary antibodies (Dako). The immunoblots were developed
with the ECL detection reagent (Amershan). All the data shown are
representative of three independent experiments.
2.5. Cyclin-dependent kinase assay
Cyclin D/cdk4-associated kinase activity was performed as described
previously [18]. Brieﬂy, quiescent and conﬂuent cells were stimulated
and harvested at the indicated times. Cyclin/cdk4 complex was immu-
noprecipitated with an anti-cdk4 antibody. Kinase activity was mea-
sured using 0.5 lg GST-pRb as the substrate and 10 lCi [c32P]ATP
at 30 C for 30 min. Reaction was stopped and analyzed by SDS–
PAGE and autoradiography.Fig. 1. U0126 blocked PGF2a-triggered ERK1-2 activation and DNA synthe
(A) or presence of U0126 or solvent control dimethyl sulfoxide (Me2SO) (B) o
analyzed by Western blot using phospho-ERK1-2 (upper panel) or ERK2 anti
PGF2a-stimulated DNA synthesis, quiescent cells were untreated (h), treated
of U0126 (0–15 lM). The percentage of S-phase cells was determined as desc
experiments leading to the same conclusions are displayed.3. Results and discussion
ERK1-2 and p38
MAPK signaling pathways are involved in a
diverse array of cellular responses. While MEK/ERK1-2 is a
well-characterized signaling pathway activated by growth fac-
tors and involved in cell proliferation, there is less evidence
linking p38MAPK activation with cell proliferation. In order
to gain insights about the early signaling mechanisms that
mediate the PGF2a mitogenic response in Swiss 3T3 cells, we
performed a Western blot analysis using speciﬁc antibodies
for the activated form of ERK1-2 (phospho-Thr
200/Tyr204).
PGF2a promoted a sustained ERK1-2 activation, inducing a
maximum increase at 5 min (Fig. 1A), remaining active for
at least 8 h (data not shown). The same results were obtained
when ERK1-2 activation was determined by an immunoprecip-
itation in vitro kinase activity assay (data not shown). Treat-
ment of Swiss 3T3 cells with U0126, a speciﬁc inhibitor of
MEK1 and thus ERK1-2 activation [19], caused a concentra-
tion-dependent reduction in PGF2a-induced ERK1-2 activation
(Fig. 1B). In order to assess whether ERK1-2 activation is re-
quired for the mitogenic eﬀect of PGF2a, we treated the cells
with U0126 before stimulation and DNA synthesis was mea-
sured. Interestingly, U0126 treatment strongly suppressed
PGF2a-induction of DNA synthesis in a dose-dependent man-
ner (Fig. 1C), whilst U0126 treatment did not signiﬁcantly af-
fect the mitogenic stimulus of fetal bovine serum (FBS)
(Fig. 1C). This result suggested that the MEK1/ERK1-2 signal-
ing pathway is critically involved in the PGF2a-proliferative
response.
PGF2a-stimulation of DNA synthesis in Swiss 3T3 cells also
requires PKC activation [14], and PKC activation has been
shown to be one of the possible pathways leading to ERK1-2sis. Quiescent cells were treated with PGF2a (300 ng/ml) in the absence
r GF109203 (D) at the indicated times. Equal amounts of proteins were
bodies (lower panel). (C) To measure the eﬀect of ERK1-2 inhibition on
with PGF2a (300 ng/ml;r) or FBS (10%;n) in the absence or presence
ribed in Section 2. Results from one out of at least three independent
Fig. 2. p38MAPK activation is required for PGF2a-triggered DNA
synthesis. (A) Cells were treated with PGF2a (300 ng/ml) for 5–60 min
or treated with NaCl (500 mM) for 30 min. Equal amounts of protein
were analyzed by Western blot using phospho-p38MAPK (upper panel)
or p38MAPK antibodies (lower panel). Band intensity was quantiﬁed;
numbers indicate the ratio of phospho-p38/p38MAPK expressed as fold
induction respect to untreated cells. Results from one out of at least
three independent experiments leading to the same conclusions are
displayed. (B) To determine the eﬀect of p38MAPK inhibition on
PGF2a-stimulated DNA synthesis, quiescent cells were untreated (h),
treated with PGF2a (300 ng/ml; r), FBS (10%; n) or LIF (100 ng/ml;
·) in the absence or presence of SB203580 (0–15 lM). The percentage
of S-phase cells was determined as described in Section 2. (C)
Quiescent cultures of stable transfected cells [empty vector (black),
p38MAPK (grey) or AF-p38MAPK (white)] were untreated (control),
treated with PGF2a (300 ng/ml), FBS (10%) or LIF (100 ng/ml). The
percentage of S-phase cells was determined as described in Section 2.
The experiments were undertaken with ﬁve independent clones of
stable transfected cells with the same results.
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ERK1-2 activation is a downstream event of PKC activation,
we used a speciﬁc PKC inhibitor (GF109203X). Interestingly,
PGF2a was still able to promote ERK1-2 activation in cells pre-
treated with GF109203X (Fig. 1D), strongly suggesting that
ERK1-2 activation is one of the early PKC-independent signals
triggered by PGF2a that are involved in the initiation of DNA
synthesis.
To gather additional insights on PGF2a-triggered signals, we
carried out a Western blot analysis using an antibody speciﬁc
for the activated form of p38MAPK (phospho-Thr180/Tyr182).
PGF2a caused an increase in phospho-p38
MAPK levels after
5 min of PGF2a addition (Fig. 2A) reaching levels comparable
to those obtained with osmotic stress induced by NaCl addi-
tion (Fig. 2A). To determine the role of this activation in the
PGF2a proliferative response, we treated the cells with the
pyridinyl imidazole SB203580, a speciﬁc inhibitor of p38MAPK.
The ability of PGF2a to induce DNA synthesis in Swiss 3T3
cells was blocked by addition of SB203580, causing maximal
inhibition at 10 lM (Fig. 2B), whilst SB203580 treatment did
not signiﬁcantly aﬀect the mitogenic stimulus of FBS or leu-
kaemia inhibitory factor (LIF) (Fig. 2B). Further conﬁrmation
that p38MAPK is critically involved in PGF2a-induction of
DNA synthesis, we generated stable cell lines expressing wild
type or dominant negative p38MAPK (AF-p38MAPK). Expres-
sion of phosphorylation-defective p38MAPK mutant with sub-
stitutions at Thr180 and Tyr182 by alanine and phenylalanine,
respectively, has been shown to block p38MAPK activation
in vivo [21]. As shown in Fig. 2C, the percentage of cells enter-
ing into the S-phase in response to PGF2a were comparable be-
tween empty vector and wild type-p38MAPK transfected cells.
In contrast, in AF-p38MAPKtransfected cells, PGF2a failed to
induce DNA synthesis (Fig. 2C). Cellular response to other
mitogenic stimuli such as FBS or LIF was unaﬀected
(Fig. 2C), consistent with a speciﬁc requirement of p38MAPK
activation in PGF2a-induction of DNA synthesis.
We have previously reported that PGF2a raised cyclin D1
protein levels at 6–9 h, reaching a plateau value after 12–
15 h and these levels remained relatively high for up to
21 h [14]. There is evidence that ERK1-2 activation raises cy-
clin D1 levels, whilst p38
MAPK activation causes the downreg-
ulation of cyclin D1 [22]. However, our results shown that
both pathways are required for the PGF2a induction of
DNA synthesis. Thus, G1-cyclins expression was determined
in PGF2a stimulated cells in the presence of MEK1 and
p38MAPK inhibitors. Treatment of cells with U0126 caused
a concentration-dependent reduction in PGF2a-triggered in-
creases of cyclin D1 levels (Fig. 3A). In contrast, cyclin D1
levels were not signiﬁcantly aﬀected in cells treated with
SB203580 (Fig. 3A). As we have previously shown, cdk4 pro-
tein levels are constitutive and are not aﬀected by any of
these treatments (Fig. 3A). Consistent with the results ob-
tained with SB203580, PGF2a-triggered increases of cyclin
D1 expression were not aﬀected in cells stable expressing
ﬂag-tagged wild type or AF-p38MAPK proteins (Fig. 3B), fur-
ther demonstrating that p38MAPK activation is not involved
in cyclin D1 expression. We also evaluated the eﬀect of
MAPK inhibitors on cyclin D/cdk4 associated kinase activ-
ity. While U0126 caused a reduction in cyclin D/cdk4 kinase
activity after PGF2a stimulation (Fig. 3C), it was not signif-
icantly aﬀected in SB203580-treated cells (Fig. 3C). These re-
sults show that the inhibitory eﬀect of SB203580 on S-phaseentry is neither due to a regulation of cyclin D1 protein levels
nor by regulating the formation and activation of cyclin
D/cdk4 kinase complex.
One event that precedes S-phase entry is hyper-phosphoryla-
tion of the pRb. To determine whether ERK1-2 and p38
MAPK
pathways converge prior to pRb phosphorylation, we analyzed
the phosphorylation state of pRb by Western blot after PGF2a
stimulation of Swiss 3T3 cells. After PGF2a or FBS addition,
pRb appeared as a more slowly migrating band corresponding
to hyperphospho-pRb protein (Fig. 4A). In contrast, this shift
in pRb migration was absent when cells were treated with
PGF2a together with either U0126 or SB203580 (Fig. 4A),
Fig. 3. PGF2a-triggered cyclin D1 expression and cyclin D/cdk4
activation require ERK1-2 but not p38
MAPKactivation. (A) Cells were
untreated (c) or treated with PGF2a in the absence or presence of
U0126 or SB203580. Cell extracts were prepared and equal amounts of
protein analyzed by Western blot using cyclin D1 (upper panel) or cdk4
antibodies (lower panel). (B) ﬂag-tagged wild type or AF-p38MAPK
stable transfected cells were untreated or treated with PGF2a. Equal
amounts of protein were analyzed by Western blot using cyclin D1
(upper panel), ﬂag (middle panel) or p38MAPK antibodies (lower
panel). All these experiments were undertaken with ﬁve independent
clones of stable transfected cells with the same results. (C) Cyclin D/
cdk4-associated kinase activity was measured in vitro after PGF2a-
stimulation of cells for 20 h in the absence or presence of U0126,
SB203580 (10 lM) or equivalent amount of solvent (Me2SO). Cyclin
D/cdk4 complexes were immunoprecipitated and kinase activity
measured using pRb-GST as substrate. Kinase reactions were analyzed
by SDS–PAGE and autoradiography. Results from one out of at least
three independent experiments leading to the same conclusions are
displayed.
Fig. 4. Involvement of ERK1-2 and p38
MAPK on pRb phosphorylation
and cyclin A expression. Cells were untreated (c), treated with FBS
(10%) or treated with PGF2a (300 ng/ml) for 25 h in the presence of
U0126 and SB203580 (10 lM). Equal amounts of protein analyzed by
Western blot using (A) a speciﬁc pRb antibody or (B) a speciﬁc cyclin
A antibody. p-pRb; phosphorylated-pRb. Results from one out of at
least three independent experiments leading to the same conclusions
are displayed.
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ing pathways are upstream of pRb. Similar results were ob-
tained when cyclin A expression was analyzed (Fig. 4B);cyclin
p38MAPK
MEK1/ERK
PKC
other eve
other even
GF109203
SB203580
U0126
Fig. 5. Summary of PGF2a triggered signals: PGF2a induces PKC, ERK1-2 an
completely blocks PGF2a induction of DNA synthesis. ERK1-2 activation is
involved in eliciting another process, strongly suggesting that the concerted
induce complete phosphorylation of pRb and S-phase entry in response to Pcyclin A is a transcriptional target of E2F and therefore down-
stream of pRb. These results further conﬁrmed that both sig-
naling pathways converge at a point prior to pRb. The
results obtained using U0126 are as anticipated, since the inhi-
bition of ERK1-2 activation blocked cyclin D1 expression and
cyclin D/cdk4 activation. However, the results obtained with
SB203580 suggest a role for p38MAPK activation in another
process, diﬀerent from activation of the cyclin D/cdk4 complex
that is upstream of pRb inhibition.
In summary, we have shown using a combination of bio-
chemical approaches and interfering mutants that both
ERK1-2 and p38
MAPK activation are essential for PGF2a-stim-
ulated S-phase entry. PGF2a promoted ERK1-2 activation by a
PKC-independent pathway, suggesting that ERK1-2 is one of
the early PKC-independent signaling events involved in
PGF2a-triggered DNA synthesis. We have also shown that
both signaling pathways converge at a point prior to pRb
phosphorylation. ERK1-2 activation is required to induce cy-
clin D1 expression, consistent with previous studies linking sus-
tained ERK activation with cyclin D1 expression and cellular
proliferation [23]. The ﬁnding that PGF2a triggers ERK1-2 acti-
vation via a PKC-independent event are also supported by
these results, since PKC inhibition blocked PGF2a’s mitogenic
response, without aﬀecting cyclin D1 mRNA/protein expres-
sion [14]. p38MAPK activation is not related to cyclin D1 D1
nt
    DNA 
synthesis
t
pRb  
d p38MAPK activation. Inhibition of any of these signaling pathways
required to induce cyclin D1 expression, while p38MAPK activation is
action of cyclin D1 gene expression and other events are required to
GF2a.
2516 A. Dekanty et al. / FEBS Letters 580 (2006) 2512–2516expression nor cyclin D/cdk4 kinase activation suggesting a
role for p38MAPK in another process, diﬀerent from cyclin D/
cdk4 activation, that is required to induce DNA synthesis
(Fig. 5). The involvement of other cyclin/cdk complexes (e.g.
cyclin E/cdk2) is the subject of current active investigation.
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